Black Diamond Therapeutics, Inc. (NASDAQ: BDTX)

Black Diamond Therapeutics is a clinical stage oncology company focused on developing MasterKey therapies that target families of oncogenic mutations in cancer.

The company's foundation relies on a deep understanding of cancer genetics oncoprotein structure and function and medicinal chemistry.

Its MasterKey compounds are designed to address a broad range of genetically defined tumors overcome resistance limit wild type mediated toxicities and penetrate the blood brain barrier to treat central nervous system disease.

Black Diamond Therapeutics generates revenue primarily through licensing agreements and collaboration deals.

In 2025 the company outlicensed its BTX 4933 program to Servier receiving an upfront payment of seventy million dollars and the right to receive future development and commercial milestones as well as tiered royalties on net sales.

The company may also earn revenue from research collaborations government grants and other partnership arrangements.

Black Diamond Therapeutics occupies a niche in the oncology market where it seeks to differentiate itself by targeting groups of related mutations with a single molecule.

Its lead candidate silevertinib is a brain penetrating irreversible EGFR inhibitor that aims to treat both classic and non classical EGFR mutations as well as the resistance mutation C797S in non small cell lung cancer and glioblastoma.

The company faces competition from large pharmaceutical firms such as AstraZeneca Boehringer Ingelheim and Janssen as well as from smaller biotech companies that are developing EGFR targeted therapies.

Black Diamond Therapeutics believes its MasterKey platform provides a competitive edge by covering multiple mutation families reducing the need for multiple drugs and by achieving strong brain penetration.

Black Diamond Therapeutics serves patients with EGFR mutated non small cell lung cancer and glioblastoma who are seeking new treatment options.

The company also works with pharmaceutical partners such as Servier to advance its pipeline through licensing and collaboration agreements.